Press Release
St. Genis-Pouilly, France, 10 May 2023
Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that members of its management team will be participating at a number of conferences in May and June 2023.
By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer.
23rd Bio€quity Europe, Dublin, Ireland, 15-16 May & 22-23 May Digital Partnering
- In person corporate presentation by Andrew Parker, CEO at 1.28pm on 5 May
2023 ASCO Annual Meeting, Chicago, IL, US, 2-6 June
- Poster presentation: A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.
Authors: Manish Patel, Matthew Ahearne, Kim Linton, Christopher Fox, David Lewis, Maureen Higgins, Brian Schwartz, Philip Beer, Michael Tees
Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Session Date and Time: 6/5/2023, 8:00 AM-11:00 AM CST
Track: Hematological Malignancies
Subtrack: Non-Hodgkin Lymphoma
Clinical Trial Registration Number: NCT05463263
Abstract #TPS7591
Poster Bd #135b
BIO International Convention Congress, Boston, MA, US, 5-8 June
International Conference of Malignant Lymphoma, Lugano, Switzerland, 13-17 June
Contacts
Step Pharma
Andrew Parker, Chief Executive Officer
contact@step-ph.com
Media Relations
Consilium Strategic Communications
Amber Fennell, Namrata Taak, Stella Lempidaki
T. +44 (0) 20 3709 5700
steppharma@consilium-comms.com
About Step Pharma
Step Pharma’s goal is to bring about a step change in how cancer is treated with targeted therapies that kill cancer cells and leave healthy cells unharmed. The Company is the world leader in CTPS1 inhibition, a new approach with the potential to yield highly selective, safe and effective treatments for both blood cancers and solid tumours.
The Company’s lead asset, STP938, has received both IND and CTA clearance to proceed into first in human trials in the US and UK for the treatment of T cell and B cell lymphomas. Clinical trials in lymphoma commenced in September 2022. STP938 has the potential to be the backbone of a multitude of cancer therapies as well as a potent monotherapy for hard-to-treat blood cancers.
Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour. Step Pharma is based in Saint-Genis-Pouilly, France, and is supported by a strong syndicate of investors led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute. More information on the company can be found at www.step-ph.com.
